Inactive Instrument

Flex Pharma Inc Stock price Nasdaq

Equities

US33938A1051

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 2.56M
Net income 2022 -31M Net income 2023 -12M EV / Sales 2022 -
Net cash position 2022 12.11M Net cash position 2023 5.61M EV / Sales 2023 -
P/E ratio 2022
-0.1 x
P/E ratio 2023
-0.17 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 84.55%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 19-07-18
Director of Finance/CFO 70 19-09-09
Director/Board Member 64 19-07-18
Members of the board TitleAgeSince
Director/Board Member 76 19-07-18
Director/Board Member 66 19-07-18
Director/Board Member 54 20-06-18
More insiders
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing effective treatments for cancers with unmet medical needs. It is developing treatments for cancers caused by dysregulated gene expression. The Company's product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The Company's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.
More about the company